159 related articles for article (PubMed ID: 38250834)
1. Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD.
Siram K; Lathrop SK; Abdelwahab WM; Tee R; Davison CJ; Partlow HA; Evans JT; Burkhart DJ
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250834
[TBL] [Abstract][Full Text] [Related]
2. Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Kumru OS; Bajoria S; Kaur K; Hickey JM; Van Slyke G; Doering J; Berman K; Richardson C; Lien H; Kleanthous H; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2023 Aug; 19(2):2264594. PubMed ID: 37932241
[TBL] [Abstract][Full Text] [Related]
3. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
5. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Brook B; Chen J; Diray-Arce J; Doss-Gollin S; Leon M; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
bioRxiv; 2021 May; ():. PubMed ID: 34031655
[TBL] [Abstract][Full Text] [Related]
6. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
7. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Cavazzoni CB; Brook B; Barman S; Chen J; Diray-Arce J; Doss-Gollin S; De Leon M; Prevost-Reilly A; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Sage PT; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
Sci Transl Med; 2022 Jan; 14(629):eabj5305. PubMed ID: 34783582
[TBL] [Abstract][Full Text] [Related]
8. Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine.
Short KK; Lathrop SK; Davison CJ; Partlow HA; Kaiser JA; Tee RD; Lorentz EB; Evans JT; Burkhart DJ
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890352
[TBL] [Abstract][Full Text] [Related]
9. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
[TBL] [Abstract][Full Text] [Related]
10. Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2.
Rodrigues KA; Rodriguez-Aponte SA; Dalvie NC; Lee JH; Abraham W; Carnathan DG; Jimenez LE; Ngo JT; Chang JYH; Zhang Z; Yu J; Chang A; Nakao C; Goodwin B; Naranjo CA; Zhang L; Silva M; Barouch DH; Silvestri G; Crotty S; Love JC; Irvine DJ
Sci Adv; 2021 Dec; 7(50):eabj6538. PubMed ID: 34878851
[TBL] [Abstract][Full Text] [Related]
11. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
13. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
Chiba S; Halfmann PJ; Iida S; Hirata Y; Sato Y; Kuroda M; Armbrust T; Spyra S; Suzuki T; Kawaoka Y
Vaccine; 2023 Sep; 41(41):6025-6035. PubMed ID: 37635002
[TBL] [Abstract][Full Text] [Related]
14. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
[TBL] [Abstract][Full Text] [Related]
15. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
18. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Lan J; Deng Y; Chen H; Lu G; Wang W; Guo X; Lu Z; Gao GF; Tan W
PLoS One; 2014; 9(11):e112602. PubMed ID: 25405618
[TBL] [Abstract][Full Text] [Related]
19. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]